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MODULATION OF THE SEROTONIN REUPTAKE TRANSPORTER IN RAW264.7 
MACROPHAGES 
Sienna Marie Arenas Malubay, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: Jennifer K. Stewart, Ph.D., Associate Professor, Department of Biology 
Serotonin (5-HT) plays an important role as both a neurotransmitter and an 
immune modulator. The serotonin reuptake transporter (SERT) clears the extracellular 
space of 5-HT, which decreases the effects of 5-HT on target cells. This study 
demonstrated that the RAW264.7 macrophage cell line expresses SERT function, 
measured by assays of 3 ~ - 5 ~ ~  uptake. The 5-HT uptake in RAW264.7 macrophages 
was more than 10-fold that of peritoneal macrophages, indicating that these cells are an 
excellent model for studying regulation of the SERT. Activation of macrophages with 
xii 
lipopolysaccharide (LPS) increased SERT activity in a time- and concentration- 
dependent manner and Western blots indicate that the increase in activity is partially due 
to LPS-induced increases in total SERT protein. Both unstimulated and LPS-stimulated 
activity was inhibited by the specific SERT inhibitor fluoxetine (ICSo = 5-8 nM) and was 
reduced by the anti-inflammatory cytokine interleulun-10. Changes in extracellular 
concentrations of interleulun-lp and tumor necrosis factor-a did not affect SERT activity. 
Introduction 
Monoamines, which include dopamine (DA), epinephrine (Epi), norepinephrine 
(NE), and serotonin (5-hydroxytryptamine; 5-HT), are found in the central nervous 
system (CNS) as well as the periphery. These molecules serve as neurotransmitters, 
hormones, and paracrine regulators and are synthesized at many sites. 
Monoamines are transported across the plasma membrane by either Type I 
neuronal or Type I1 extra-neuronal transporters. The Type I transporters are sodium- 
dependent and include the dopamine transporter (DAT), the norepinephrine transporter 
(NET), and serotonin transporter (SERT). All of these transporters have more than one 
substrate. For instance, the NET has a two-fold higher affinity for NE than for Epi but 
transports both across the cell membrane (12). These Type I transporters are generally 
inhibited by cocaine. Though called the neuronal transporters, the Type I transporters 
also are found in non-neuronal cells. The Type I1 extra-neuronal transporters include 
members of the organic cation transporter family (OCT1, OCT2, and OCT3) (12). The 
Type I1 transporters have an affinity for a broad range of substrates. OCT3 also has been 
called the extra-neuronal monoamine transporter (EMT) (12). These Type I1 transporters 
usually are inhibited by catecholamine metabolites, such as metanephrine (2; 12). 
2 
Serotonin and its receptors: 
Serotonin (5-HT) is an indolamine derived from the amino acid tryptophan. L- 
tryptophan is converted to 5-hydroxytryptophan (5-HTP) by tryptophan 5-hydroxylase. 
Next, 5-HTP is converted to 5-HT by 5-HTP decarboxylase (Figure 1) (10). 
Serotonin is made primarily by serotonergic neurons found in the midbrain and 
medulla of the mammalian central nervous system (CNS) and in the enterochromaffin 
cells of the gastrointestinal tract (GI). In the CNS, vesicles in pre-synaptic neurons store 
5-HT until released into the synapse. Once in the synaptic cleft, 5-HT can bind to its 
receptors on post-synaptic neurons. Similarly, in the periphery, 5-HT is released into the 
extracellular space in order to bind to its receptors. While synthesized primarily by 
enterochromaffin cells outside of the CNS, 5-HT also can be picked up and stored by 
many different non-neuronal cells, such as platelets and mast cells, for later release (29). 
Seven families of 5-HT receptors (5-HT1.7) have been identified to date. Some of 
these receptors also have subtypes and have been classified by their structure, function, 
and pharmacology (16). The many subtypes of the 5-HT1 receptor family are coupled to 
Gi/Go proteins. Generally these receptors mediate a decrease in the concentration of 
cyclic adenosine 5'-monophosphate (CAMP) in the cytosol through the inhibition of 
adenylyl cyclase, or the receptors mediate opening of potassium ion (Kf) channels to 
hyperpolarize the neuron (13). These receptors affect cerebral vasoconstriction, neuronal 
inhibition, and behavioral effects, such as sleep, thermoregulation, and anxiety. Whereas 
the members of the 5-HT1 receptor family are generally found in the CNS, the three 
members of the 5-HT2 family are found in both the CNS and periphery. These G,/Gll- 
coupled proteins increase the amount of inosotol triphosphate (IP3) and diacylglycerol 
(DAG) found in the cell and affect neuronal excitation, smooth muscle contraction, and 
platelet aggregation (13). The 5-HT3 receptor is a serotonin-gated sodiurn/potassium 
(Na+/K+) channel that is found in both the CNS and peripheral nervous system (PNS). It 
stimulates rapid depolarization of the plasma membrane, which in turn leads to neuronal 
excitation and anxiety (13). Both the 5-HT4 receptor and 5-HT7 receptors are G,-coupled 
proteins that function in the CNS and GI tract by increasing the levels of CAMP available 
within the cell. The 5-HT4 receptor affects neuronal excitation and may have a role in 
peristalsis (16). Not much is known about the effects of the 5-HT7 receptor, though it 
may have a role in mood, learning, neuroendocrine, and vegetative disorders (16). 
Although the 5-HT5 and 5-HT6 receptors have been identified, little is known about them 
(see Table 1 for summary). 
Macrophages: 
Macrophages are mononuclear phagocytes that play an important role in both 
innate and acquired immunity. Pluripotent hematopoietic stem cells from bone marrow 
can differentiate into monocytes, the precursor of macrophages. Monocytes travel 
throughout the body in the circulatory system. Through the process of extravasation, 
monocytes leave the blood vessels and develop into tissue-resident macrophages. 
Macrophages are the first line of defense in the innate immune system. They are 
one of the first cells to appear at the site of injury or infection and work to clear the area 
of pathogens and debris through phagocytosis. Bacteria or other pathogens are ingested 
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by macrophages in a phagosome, which later binds to a lysozome containing digestive 
enzymes to break down the ingested material (21). In addition, macrophages produce 
reactive oxygen species, such as nitric oxide. These are released at the site of infection in 
an oxidative burst and kill invading pathogens (21). 
Macrophages synthesize cytokines in response to stimuli, such as 
lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria. The 
pro-inflammatory cytokines (TNF-a, IL-ID, IL-6, IL-8, and IL-12) released by 
macrophages further develop and coordinate the immune response (21). These cytokines, 
along with other chemotactic factors secreted by the macrophage, work to further activate 
the macrophage, as well as other immune cells, and signal additional immune cells to the 
site of infection (21; 30). The macrophage also produces anti-inflammatory cytokines 
such as IL-10 that counteract the pro-inflammatory cytokines, and the macrophage 
functions in the acquired immune response as an antigen-presenting cell. After bacteria 
have been digested, an antigen fragment is bound to the macrophage's major 
histocompatibility (MHC) class I1 molecule and is brought to the plasma membrane. The 
helper T cells then bind to the MHC-II+antigen complex with its CD4 protein (44). 
Previous studies indicate that macrophages take up monoamines, such as the 
catecholamine NE (2; 20). Recently in our lab, Meghan Rudd showed that the SERT, 
which transports DA as well as serotonin, is functional in mouse peritoneal macrophages 
(40). 
5 
Serotonin and the Immune System: 
The role of 5-HT as a CNS neurotransmitter has been extensively studied, but its 
role in the periphery is not as well known. Serotonin has been shown to affect a variety 
of systems in the body. In the cardiovascular system, for example, 5-HT works as a 
vasoconstrictor, and in the digestive system, 5-E-IT stimulates smooth muscle 
contractions, such as peristalsis (13; 29). Serotonin also affects many of the cells in the 
immune system. 
Different types of 5-HT receptors are found on many immune cells. Recently, 
mRNA for serotonin receptor subtypes lE, 2A, 3, 4 and 7 (5 -mRIE,  5-HTRZA, 5-HTR3, 
5-HTR4, and 5-HTR7) have been found in monocytes (1 1). Serotonin induces the release 
of chemotactic factors, such as IL-16, by peripheral blood mononuclear cells (26). In 
addition, 5-HT has a role in delayed-type hypersensitivity (for review: (29)). 
Serotonin also has been shown to affect macrophage phenotype and function. For 
example, in mice treated with para-chlorphenylalanine (pCPA), a tryptophan hydroxylase 
inhibitor, the resulting 5-HT depletion decreased splenic macrophage activation of T- 
cells (29; 46). Moreover, 5-HT, acting through the 5-HTIA receptor, upregulates the 
macrophage's phagocytic activity (14). In addition, 5-HT can modulate cytokine 
production in macrophages. For example, serotonin inhibits the production of LPS- 
induced TNF-a in macrophages in a dose-dependent manner (1). Although high levels of 
5-HT can reduce IL-6 and TNF-a production, depletion of 5-HT with pCPA also 
decreases the production of IL-6 and TNF-a (25). Similar effects are observed on the 
production of pro-inflammatory cytokine IFN-y and the anti-inflammatory cytokine IL- 
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10 (24). These findings suggest that low concentrations of 5-HT are needed for 
production of these cytokines, but high levels of 5-HT are inhibitory (24; 25). In 
addition, 5-HT-induced increases in the production of IL-6, IL-1P, and IL-8 appear to be 
mediated by 5-HT4 and 5-HT7 receptors (1 1). 
Furthermore, 5-HT may play a role in lipid storage in monocytes, which are 
precursors of macrophages. Suguro et al. have found that 5-HT causes an increase in the 
expression of the acyl-coenzymeA:cholesterol acyltransferase-1 (ACAT-1) protein in 
monocytes (42). ACAT-1 changes free cholesterol into cholesterol esters for storage. 
The storage of lipids in macrophages leads to the formation of foam cells, which 
participate in the formation of atherosclerotic plaque (27). 
Function and regulation of the SERT: 
The serotonin reuptake transporter (SERT) is a protein with twelve membrane- 
spanning domains (4). It is found on many different cell types including neurons, 
platelets, mast cells, and macrophages. The SERT takes up 5-HT, decreasing its 
concentration in the synapse or extracellular space, which decreases the interaction of 5- 
HT with 5-HT receptors (18). 
Changes in SERT function have been implicated in several neurological diseases 
including clinical depression and obsessive-compulsive disorders (32; 45). As such, the 
pharmacology of the SERT has been examined thoroughly. It is the target of many 
antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs) including 
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fluoxetine (prozacB), and is modulated by less specific uptake inhibitors, such as tricyclic 
antidepressants and cocaine (4; 45). 
The SERT gene is a member of a large family made up of transporters genes, such 
as the NET gene and DAT gene (4; 43). All of the transporters are Na'ICl- dependent 
and can be blocked by cocaine (2; 4; 37). Specifically, the SERT cotransports 5-HT with 
Na' and C1- ions into the cell while transporting K' ions into the extracellular space. 
Voltage clamp studies indicate that Na', C1-, and 5-HT bind to the SERT inducing a 
conformational change that allows them to enter the cytosolic space. Once this exchange 
has been made, K' binds to a site on the SERT causing it to return to the original 
conformation and allowing K+ to exit into the extracellular space (6; 36). 
Many recent studies have investigated SERT regulation. SERT has been shown 
to interact with the SNARE protein syntaxin 1A (SynlA) (17), and treatment with 
botulinum C1 toxin, which cleaves SynlA, causes a decrease in SERT function in 
thalamacortical neurons (36). 
Other laboratories have examined the role of phosphorylation on the expression 
and function of the SERT. Protein phosphatase 2A (PP2A) interacts with the SERT and 
down-regulate its activity (38). The SERT also is readily phosphorylated by protein 
kinase A (PKA) and protein lunase C (PKC). Whereas increased PKA phosphorylation 
has little effect on activity, increased phosphorylation with PKC causes a down- 
regulation of 5-HT transport by the SERT (5). In addition, PKC works in a biphasic 
manner in its regulation of the SERT. Activated PKC phosphorylates the SERT serine 
residues within 5 min, inhibiting the SERT (23). After 30 min, activated PKC 
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phosphorylates SERT threonine residues, causing SERT endocytosis and further 
inhibition of its activity (23). Moreover, amphetamines, cocaine, and a variety of SERT 
substrates, such as 5-HT, modulate PKC-dependent SERT phosphorylation and modulate 
surface distribution (22; 37). 
Protein kinase G (PKG) and p38 mitogen-activated protein lunase (MAPK) play a 
role in up-regulating SERT activity (34; 41; 48-50). The inhibition of p38 MAPK by 
PD 1693 16 (4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole) has shown 
that p38 MAPK is necessary for maintaining SERT function (41). There is now evidence 
that p38 MAPK up-regulates the SERT through PP2A. Although p38 MAPK and PP2A 
activate the SERT, these enzymes do not regulate insertion of the SERT into the plasma 
membrane (48). In contrast, PKG promotes an increase of SERT surface density (49). 
Treatment with sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, causes a rise in 
cGMP, which increases SERT activity and density (50). Adenosine, acting through the 
adenosine receptor, appears to up-regulate SERT activity via this pathway (49). Figure 2 
summarizes major pathways regulating the SERT 
The SERT has been extensively studied in the CNS or in transfected cells, but 
little studied in other cell types in which this protein is naturally expressed. Nevertheless, 
Meghan Rudd in our laboratory found that recruited peritoneal macrophages express 
SERT mRNA as well as functional protein (40). Furthermore, using reverse transcriptase 
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PCR (RT-PCR) our laboratory has revealed that the RAW264.7 macrophage cell-line 
also expresses SERT mRNA (39). In the study presented here, we examined the 
regulation of SERT activity within this cell line. 
Methods and Materials 
RA W264.7 Macrophages 
Murine macrophages from the RAW264.7 cell line (American Type Cell Culture, 
Manassas, VA) were cultured in complete RPMI containing RPMI-1640 (Gibco brand, 
Invitrogen, Carlsbad, CA) with 10% heat-inactivated fetal bovine serum (Cellgro brand, 
VWR, West Chester, PA), 1% L-glutamine, 1% minimal essential medium vitamins, 1% 
nonessential amino acids, 100 Unitslml penicillin, 100 pglml streptomycin, and 10 mM 
HEPES buffer at pH 7.4 (Gibco brand, Invitrogen, Carlsbad, CA). The cell cultures were 
maintained at 37 "C in 5% C02  in 75 cm2 tissue culture flasks (Corning brand, Fisher 
Scientific, Hampton, NH). The cultures were sub-cultured twice weekly. 
Recruited Macrophages 
Female CBAIJ mice (6-8 weeks of age) were obtained from Harlan (Indianapolis, 
IN) and housed in the Virginia Commonwealth University animal facilities under the 
guidelines of the University Animal Care and Use Committee. Macrophages were 
recruited via an intraperitoneal injection with 0.5 ml of a 1: 1 complete Freund's Adjuvant 
(CFA; Sigma-Aldrich, St. Louis, MO) and phosphate buffered saline (PBS; Gibco brand, 
Invitrogen, Carlsbad, CA). After two weeks, the mice were euthanized with COz. The 
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recruited peritoneal macrophages were harvested, washed with Hank's Balanced Salt 
Solution (Gibco brand, Invitrogen, Carlsbad, CA) and allowed to adhere for 4 h in 12- 
well tissue culture plates (Costar brand, Fisher Scientific, Hampton, NH). Non-adherent 
cells were discarded, and adherent cells were washed with complete RPMI and treated 
with vehicle (media alone) or activated with lipopolysaccharide (LPS; E. coli serotype 
055:B5; Sigma-Aldrich, St. Louis, MO). The macrophages were maintained in complete 
RPMI at 37 "C in 5% C 0 2  for the times designated in each experiment. 
Uptake of ~ H - S H T  ~ s s q  
RAW264.7 macrophages were plated in 12-well tissue culture plates (1.5 x lo6 
cellslwell) and were treated as designated in each experiment. The plates were incubated 
at 37 "C in 5% C 0 2  overnight, allowing the cells to grow to a density of approximately 3 
x lo6 cellslwell. The uptake assay is a modification of Ganapathy et al. (15), Horschitz et 
al. (19), and Rudd et al. (40). 
Immediately prior to the assay, the cells were washed twice with 1 ml of room- 
temperature sucrose Hepes (SH) uptake buffer containing 140 mM NaCl (LiCl or choline 
chloride for certain experiments), 2 mM KCl, 1 mM CaC12, 1 mM MgC12, 5 mM glucose, 
10 mM Hepes (pH 7.4), and 320 rnM sucrose. The macrophages were then preincubated 
for 5 min with SH uptake buffer containing 250 yM ascorbic acid (Sigma-Aldrich, St. 
Louis, MO), 10 yM pargyline (Sigma-Aldrich, St. Louis, MO), and vehicle or various 
concentrations of inhibitors. Radiolabeled serotonin (25 nM, 18 Cilmmol; Vitrax, 
Placentia, CA) was added, and incubation continued for 10 min (except in time course 
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experiments). All incubations were conducted at room temperature. The uptake buffer 
was removed, and cells were washed twice with 2 ml of SH buffer. The cells were lysed 
with 800 p1 of 0.2 N NaOH containing 1% SDS, and the lysate was transferred to 10 ml 
of Scintisafe scintillation fluid (Fisher Scientific, Hampton, NH). The wells were washed 
with an additional 600 p1 of the NaOHISDS (Sigma-Aldrich, St. Louis, MO), and the 
wash was transferred to the scintillation fluid. Radioactivity was measured with a 
Beckman LS6000IC scintillation counter (Beckrnan Coulter, Inc., Fullerton, CA). 
Western Blotting 
Cultured cells were lysed with 100-300 p1 of ice cold buffer containing 0.05 M 
Tris (pH 7.5), 0.3 M NaCl, 2 mM EDTA, 1 % Triton-X 100, 2 pglml leupeptin, 1 pglml 
aprotinin, and 0.2 mM phenylmethylsulfonyl fluoride. Lysate protein concentrations 
were determined with the BioRad protein assay (BioRad Laboratories, Hercules, CA). 
Proteins (50 pg, or 30 pg for connective-tissue-derived mast cells) were separated 
by SDS-PAGE on 10% polyacrylamide gels (BioRad Laboratories, Hercules, CA). The 
separated proteins were transferred via electroblotting to nitrocellulose membranes 
(BioRad Laboratories, Hercules, CA) and incubated 1 h at room temperature in a 
blocking solution of 500 ml Tris-buffered saline containing 0.1% Tween-20 (TBST) and 
3% dry milk. The membranes were then incubated overnight at 4 OC with either goat 
anti-mouse SERT (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit anti-rat 
SERT (Chemicon, Temecula, CA) diluted 1:500. The membranes were washed three 
times with TBST, and then incubated with either a 1:5000 dilution of donkey anti-goat 
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IgG conjugated with horseradish peroxidase (HRP) or goat anti-rabbit IgG-HRP (Santa 
Cruz Biotechnology, Inc). The membranes were washed four times with TBST, and 
enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ) was used to 
visualize immunoreactive proteins. 
To control for loading of protein, blots were stripped with Restore Stripping 
Buffer (Pierce Biotechnology, Inc., Rockford, IL) and reprobed for p-actin by incubating 
1 h with a 1:5000 dilution of mouse monoclonal anti-p-actin (Sigma-Aldrich, St. Louis, 
MO), then washed with TBST. The membrane was incubated with a 1:5000 dilution of 
HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) 
before washing and visualizing with enhanced chemiluminescence (Amersham 
Biosciences, Piscataway, NJ). 
MTT Cell Viability Assay 
The MTT assay protocol is an adaptation of Mosmann (28), Carmichael et al. (7), 
and Pozzolini et al. (33). RAW264.7 macrophages were plated in 12-well cell culture 
plates (Costar brand, Fisher Scientific, Hampton, NH) at a density of 1.5 x lo6 cells/well. 
The cells were treated with vehicle (media alone) or LPS (30 nglml) and incubated at 37 
"C in 5% C02 for 24 h. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny1tetrazo1ium 
bromide; Sigma-Aldrich, St. Louis, MO) was added to each well at a final concentration 
of 0.5 mglml and incubated for an additional 4 h. All media was then aspirated, and cells 
were lysed with a buffer containing sodium dodecyl sulfate (SDS; Sigma-Aldrich, St. 
Louis, MO) dissolved in 50% N,N-dimethyl-formamide (DMF; Sigma-Aldrich, St. Louis, 
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MO) and incubated overnight at 37 "C. The plate was read with the pQuant Universal 
Microplate Reader (Bio-Tek Instruments, Winooski, VT) at 570 nm. 
Measurement of TNF-a and IL-Ip 
Extracellular TNF-a and IL-6 concentrations were assayed with the OptEIA Multi 
Component ELISA Set for Mouse TNF-a and Mouse IL-IP, respectively (BD 
Biosciences, San Diego, CA). The assays were performed in accordance with the 
manufacturer's protocols. The plates were read at 450 and 570 nm with a pQuant 
Universal Microplate Spectrophotometer (BioTek Instruments, Winooski, VT). TNF-a 
and IL-1P concentrations were calculated with KC4 software (BioTek Instruments, 
Winooski, VT). 
RNA Isolation 
RAW264.7 macrophages were cultured in 6-well tissue culture plates (Costar 
brand, Fisher Scientific, Hampton, NH) and treated with vehicle (media alone) or LPS 
(30 nglml) as designated per experiment. Total RNA was extracted from approximately 
six million cells in culture with TRI-Reagent (Molecular Research Center, Cincinnati, 
OH) according to the procedures provided by the manufacturer. RNA samples were 
stored at -70 "C. 
Reagents 
Fluoxetine used in 3 ~ - 5 ~ ~  uptake assays was a gift from Eli Lilly (Indianapolis, 
IN). All other reagents, including IL-10 and unlabeled 5-HT, were purchased from 
Sigma-Aldrich (St. Louis, MO). 
Data Analyses 
Analysis of variance (ANOVA) and Tukey's multiple comparison test were used 
to evaluate effects of transport inhibitors and cytokines on 3 ~ - 5 ~ ~  uptake. ICS0 values 
were calculated with Prism software (Graphpad, San Diego, CA). For experiments with 
only two treatments, a t-test was used to compute statistical significance. Differences 
were considered statistically significant at p10.05. 
Results 
Comparison of 3 ~ - 5 ~ ~  uptake in RA W264.7 macrophages and peritoneal macrophages 
To calculate specific uptake of 3 ~ - 5 ~ ~ ,  the non-specific uptake, measured in the 
presence of 25 pM non-radioactive 5HT, was subtracted from the total uptake of 3 ~ - 5 ~ ~  
(Figure 3). The specific uptake of 'H-SHT in RAW264.7 macrophages was surprisingly 
high. Uptake of 'H-~HT, measured over 10 min, in these cells was 21-fold that 
previously measured in mouse peritoneal macrophages (40) and approximately 11 times 
that measured in primary peritoneal macrophages in this study (Figure 4). In this study, 
primary cells were incubated with twice the concentration of 3 ~ - 5 ~ ~  used in either 
assays of RAW264.7 cells or previous assays of primary cells. 
LPS activation of RA W264.7 macrophages increased 5-HT uptake 
Lipopolysaccharide (LPS) activation of RAW264.7 macrophages stimulated a 
2.5-fold increase of 'H-~HT specific uptake compared to 3 ~ - 5 H T  specific uptake in cells 
treated with media alone (vehicle) (Figure 5). Moreover, specific uptake was sodium 
dependent in both vehicle- and LPS-treated macrophages (Figure 5). When pre- 
incubated with SH uptake buffer containing either lithium chloride (LiCl) or choline 
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chloride, uptake was inhibited more than 90% compared to uptake by macrophages 
incubated in SH uptake buffer containing NaCl. LPS did not significantly affect uptake 
measured in LiCl or choline chloride buffer. 
In order to verify the role of the SERT in the uptake of 5-HT in RAW264.7 
macrophages, 3 ~ - 5 ~ ~  uptake assays in the presence of the SSRI fluoxetine were 
performed (Figures 6A and 7A). In both vehicle- and LPS-treated macrophages, uptake 
of 3 ~ - 5 ~ ~  was reduced as the concentration of fluoxetine was increased. The IC50 of 
fluoxetine inhibition was 5.7 nM for 5-HT transport in vehicle-treated macrophages 
(Figure 6B) and 7.7 nM in LPS-treated cells (Figure 7B). These IC50 values are similar to 
those reported for the SERT in mouse peritoneal macrophages and in human cells (3; 40). 
LPS modulation of SERT activity was time- and concentration-dependent 
Up-regulation of SERT activity by LPS activation was time-dependent (Figure 8). 
RAW264.7 macrophages were treated with vehicle (media only) or 30 ng/ml LPS and 
incubated at 4 h, 12 h, or 24 h prior to assay of 3 ~ - 5 ~ ~  uptake. At 4 h and 12 h after 
treatment, there was no significant difference in SERT activity in vehicle-treated and 
LPS-treated cells. At 24 h after LPS (30 ng/ml), SERT activity increased approximately 
2.3-fold compared to SERT activity in vehicle-treated cells. 
Although we have routinely used 30 - 50 nglml LPS to activate macrophages, and 
30 nglml LPS was used in initial experiments, a concentration-response curve revealed 
that 3 ~ - 5 ~ ~  specific uptake peaked when cells were treated with 1 - 3 ng/ml LPS 
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(Figure 9). Treatment with 1 ng/ml or 3 ng/ml LPS elevated SERT activity in the 
macrophages by approximately 3.3 times compared to vehicle-treated cells. 
IL-10 decreased 5-HT uptake 
When the anti-inflammatory cytokine interleukin- 10 (IL- 10; 20 ng/ml) was added 
to the cell media 2 h prior to treatment with vehicle or LPS (26 h before measurement of 
3 ~ - 5 ~ ~  uptake), SERT activity decreased by approximately 45% in vehicle-treated cells 
and 61% in LPS-treated cells (Figure 10A). An MTT (3-(4,5-dimethylthiazol-2-y1)-2,5- 
diphenyltetrazolium bromide) viability assay demonstrated no significant differences in 
cell viability that could account for the differences in SERT activity observed 24 h after 
vehicle, LPS (30 ng/ml), or IL-10 (20 ng/ml) (Figure 10B). Furthermore, IL-10 (20 
ng/ml) also inhibited SERT activity roughly 41% in macrophages activated with low 
levels of LPS (3 ng/ml) (Figure 1 I). 
Mechanism for SERT upregulation by LPS 
Western blotting was used to determine whether LPS increased SERT protein in 
RAW264.7 macrophages (Figure 12). Connective tissue mast cells (CTMC), a positive 
control, produced a distinct band at approximately 70 kDa as expected (8; 35). No 
immunoreactive SERT was observed in L929 fibroblasts, which served as the negative 
control. The estimated molecular weight of immunoreactive SERT detected in both 
vehicle- and LPS-treated RAW264.7 lysates was 75 kDa, whereas the kDa of the SERT 
in CTMC was 70 kDa. Interestingly, the density of immunoreactive SERT from LPS- 
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treated RAW264.7 macrophages was greater than that in the vehicle-treated cells (n=3) 
suggesting that LPS increased total SERT protein; however, the differences were not 
statistically significant. In order to determine if LPS also increases SERT mRNA, RNA 
samples have been extracted and frozen for future real-time PCR analysis. 
LPS-activated macrophages produce nitric oxide (NO), which activates the SERT 
through the PKGIp38 MAPK pathway (for review: see Figure 2)(48-50). To investigate 
whether PKG is involved in the LPS-induced upregulation of SERT activity, the 3 ~ - 5 ~ ~  
uptake assay was performed in the presence of LY83583, a guanylyl cyclase (GC) 
inhibitor (Figure 11). As expected, there was a significant increase in 5-HT uptake in 
cells treated with LPS (30 nglml) compared to those treated with media only (vehicle). 
When vehicle- or LPS-treated cells were incubated with LY83583 (10 pM) or its 
appropriate vehicle (0.1% ethanol) for 24 h, the inhibitor killed the cells (data not 
shown). When cells were treated with LPS or vehicle for 24 h and incubated with the 
inhibitor for 20 min prior to the 3 ~ - 5 ~ ~  uptake assay, there were no significant 
differences between those incubated with LY83583 and those without LY83583. These 
findings suggest that short-term inhibition of GC does not affect SERT activity in 
RAW264.7 macrophages, although others have demonstrated short-term effects of this 
inhibitor on the SERT in other cells (49). 
LPS-activated macrophages release pro-inflammatory cytokines such as tumor 
necrosis-alpha (TNF-a) and interleukin- 1 g (IL- 10). Preliminary data from enzyrne- 
linked immunosorbent assays (ELISA) indicated that there is more TNF-a (1.3-fold) and 
IL-1P (6.3-fold) present in the cell media of cells treated with 30 nglml LPS than those 
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treated with 1 nglml LPS (Figure 14A and 14B). Yet, the lower concentration of LPS is 
the optimal stimulus for SERT activity. Despite evidence that TNF-a and IL-1P 
stimulate increased SERT activity in some cell types (47), these preliminary data suggest 
that these cytokines are not the only stimulus for 5-HT during macrophage activation. 
Discussion 
This study demonstrates that RAW264.7 macrophages express high SERT 
activity, more than 10-fold that observed in peritoneal macrophages in this study or in 
previous studies in our laboratory (40). Therefore, this cell line is an excellent model for 
studying regulation of the SERT. 
This study shows for the first time that SERT activity is increased by LPS- 
induced activation of macrophages in a time- and concentration-dependent manner. 
Because more than 12 h of LPS activation is required to detect increased SERT activity, 
it is probable this rise in 5-HT uptake is not due simply to a translocation of the SERT 
protein. Moreover, Zhu et al. suggest that PKG plays a role in the exocytosis of the 
SERT protein from vesicles in the cytosol to the plasma membrane (49); however, assay 
of 3 ~ - 5 ~ ~  uptake in the presence of a PKG inhibitor, LY83583, failed to significantly 
decrease SERT activity. Western blotting suggested that there was more SERT protein 
present in LPS-activated macrophages than in vehicle-treated cells. Conversely, 
previously we were unable to detect effects of LPS on SERT protein in recruited 
peritoneal macrophages (40), although recruitment may have maximally stimulated 
SERT activity prior to LPS treatment. 
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The mechanism for IL-10-induced reduction of SERT activity in this study is 
unknown, but it has been shown that IL-10 can work through the STAT3 pathway in 
order to decrease proliferation of macrophages (31). Using an MTT viability assay, 
however, we could not find any significant change in cell viability induced by IL-10 (20 
ng/ml) and LPS (30 ng/ml). It is conceivable, however, that high concentrations of LPS 
(90 ng/ml) do not increase SERT activity because cell viability is reduced. 
Because the pro-inflammatory cytokines stimulate p38 MAPK activity, it is not 
surprising that these cytokines also increase SERT activity (9). For example, TNF-a and 
IL-1P, pro-inflammatory cytokines, have been shown to stimulate 5-HT uptake in a rat 
embryonic neuronal cell line and in midbrain synaptosomes through the p38 MAPK 
pathway (47). Data from our lab, however, show that more TNF-a is secreted by 
RAW264.7 macrophages at higher concentrations of LPS, and the increase in 5-HT 
uptake peaks at approximately 1 ng/ml LPS. These findings suggest that while pro- 
inflammatory cytokines play a role in the LPS-stimulation of the SERT, there may be 
additional stimulation through other pathways. 
In summary, this study demonstrates that the RAW264.7 macrophage cell line is a 
useful model system to study the SERT and its regulation. Moreover, this is the first 
study to demonstrate that LPS-activation of macrophages increases SERT activity. These 
findings may have clinical implications in patients taking SSRIs such as fluoxetine 
(prozacQ), sertraline (zoloftQ), and paroxetine (paxilB). As these SSRIs inhibit SERT 
activity, there are higher concentrations of extracellular 5-HT, allowing for increased 
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binding to 5-HT receptors. This may lead to an increase in the actions caused by the of 
5-HT on macrophages such as decreased production of TNF-a (25). 
List of References 
1. Arzt E, Costas M, Finkielman S and Nahmod V. Serotonin inhibition of tumor 
necrosis factor-alpha synthesis by human monocytes. Life Sci 48: 2557-2562, 1991. 
2. Balter NJ and Schwartz SL. Accumulation of norepinephrine by macrophages and 
relationships to known uptake processes. J Pharmacol Exp Ther 201: 636-643, 
1977. 
3. Barker EL and Blakely RD. Structural determinants of neurotransmitter transport 
using cross-species chimeras: studies on serotonin transporter. In: Methods in 
Enzymology, Volume 296, Neurotransmitter Transporters, edited by Amara SG. 
New York: Academic Press, 1998, p. 475-498. 
4. Barker EL and Blakely RD. Norepinephrine and serotonin transporters: molecular 
targets of antidepressant drugs. In: Psychophamacology - The Fourth Generation of 
Progress, edited by Bloom FE and Kupfer DJ. American College of 
Neuropsychopharmacology, 1995. 
25 
5. Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A and 
DeFelice LJ. Regulated phosphorylation and trafficlung of antidepressant-sensitive 
serotonin transporter proteins. Biol Psychiatry 44: 169-178, 1998. 
6. Cao Y, Li M, Mager S and Lester HA. Amino acid residues that control pH 
modulation of transport-associated current in mammalian serotonin transporters. J 
Neurosci 18: 7739-7749, 1998. 
7. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchel JB. Evaluaiton of a 
tetrazolium-based semiautomated colorimetric assay: assessment of 
chemosensitivity testing. Cancer Res 47: 936-942, 1987. 
8. Chemicon International. Rabbit anti-serotonin transporter affinity purified 
polyclonal antibody. 2005. 
9. Clerk A, Harrison JG, Long CS and Sugden PH. Pro-inflammatory cytokines 
stimulate mitogen-activated protein kinase subfamilies, increase phosphorylation of 
cJun and ATF2 and upregulate cJun protein in neonatal rat ventricular myocytes. J 
Mol Cell Cardiol3 1: 208 1-2099, 1999. , 
10. Cooper JR, Bloom FE and Roth RH. The Biochemical Basis of 
Neurophamzacology. New York, NY: Oxford University Press, 1996. 
26 
11. Durk T, Panther E, Muller T, Sorichter S, Ferrari D, Pizzirani C, Di Virgilio F, 
Myrtek D, Norgauer J and Idzko M. 5-Hydroxytryptamine modulates cytokine and 
chemokine production in LPS-primed human monocytes via stimulation of different 
5-HTR subtypes. Int Immunol 17: 599-606,2005. 
12. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane 
transporters in the inactivation of peripheral catecholamines. Phunnucol Ther 91: 
35-62,2001. 
13. Frazer A and Hensler JG. Serotonin receptors. In: Basic Neurochemistry: 
Molecular, Cellular, and Medical Aspects, edited by Siege1 GJ, Agranoff BW, 
Albers RW, Fisher SK and Uhler MD. Philadelphia, PA: Lippincott-Raven Press, 
1999. 
14. Freire-Garabal M, Ntiiiez MJ, Balboa J, L6pez-Delgado P, Gallego R, Garcia- 
Caballero T, Fernindez-Roe1 MD, Brenlla J and Rey-Mkndez M. Serotonin 
upregulates the activity of phagocytosis through 5-HTIA receptors. Br J Phurmucol 
139: 457-463,2003. 
15. Ganapathy P, Prasad PD and Leibach FH. Use of human placenta in studies of 
monoamine transporters. In: Methods in Enzymology, Vol. 296 Neurotransmitter 
Transporters, edited by Amara SG. New York, NY: Academic Press, 1998, p. 278- 
290. 
16. Glennon RA, Dukat M and Westkaemper RB. Serotonin receptor subtypes and 
ligands. In: Psychopharmacology - The Fourth Generation of Progress, edited by 
Bloom FE and Kupfer DJ. New York, NY: Raven Press, 1995, p. 415-429. 
17. Haase J, Killian A-M, Magnani F and Williams C. Regulation of the serotonin 
transporter by interacting proteins. Biochem Soc Trans 29: 722-728,2001. 
18. Horschitz S, Hummerich R and Schloss P. Structure, function, and regulation of the 
5-h ydrox ytryptamine (serotonin) transporter. Biochem Soc Trans 29: 728-732, 
2001. 
19. Horschitz S, Hummerich R and Schloss P. Functional coupling of serotonin and 
noradrenaline transporters. J Neurochem 86: 958-965, 2003. 
20. Inoue K and Creveline CR. The macrophage as a site of extraneuronal uptake and 
0-methylation of norepinephrine. Biogenic Amines 9: 291-294, 1993. 
21. Janeway CA, Travers P, Walport M and Capra JD. Zmrnunobiology: The Immune 
System in Health and Disease. New York, NY: Garland Publishing, 1999. 
22. Jayanthi LD and Ramamoorthy S. Regulation of monoamine transporters: influence 
of psychostimulants and therapeutic antidepressants. AAPS J 7: E728-E738, 2005. 
28 
23. Jayanthi LD, Samuvel DJ, Blakely RD and Ramamoorthy S. Evidence for biphasic 
effects of protein lunase C on serotonin transporter function, endoc ytosis, and 
phosphorylation. Mol Pharnzacol67: 2077-2087,2005. 
24. Kubera M, Kenis G, Bosmans E, Scharpk S and Maes M. Effects of serotonin and 
serotonergic agonists and antagonists on the production of interferon-y and 
interleukin-10. Neuropsychopharmacology 23: 89-98,2000. 
25. Kubera M, Maes M, Kenis G, Kim Y-K and L a s h  W. Effects of serotonin and 
serotonergic agonists and antagonists on the production of tumor necrosis factor a 
and interleukin-6. Psychiatry Res 134: 25 1-258,2005. 
26. Laberge S, Cruikshank WW, Beer DJ and Center DM. Secretion of IL-16 
(lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in 
vitro. J Immunol 156: 310-315, 1996. 
27. Miyazalu A, Sakashita N, Lee 0, Takahashi K, Horiuchi S, Hakamata H, 
Morganelli PM, Chang CC and Chang TY. Expression of the ACAT-1 protein in 
human aterosclerotic lesions and cultured human monocytes-macrophages. 
Arterioscler Thrornb Vasc Biol 18: 1568-1574, 1998. 
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application 
to proliferation and cytotoxicity assays. J Irnmunol Methods 65: 55-63, 1983. 




















